Editas Medicine has expanded its partnership with Azzur Cleanrooms on Demand (COD) for the manufacturing of EDIT-301, its experimental cell-based gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia. If approved, the scaling up of EDIT-301 needs to follow current good manufacturing practice (cGMP) standards — set…
News
Researchers have developed a new way of delivering gene-editing therapies for people with blood disorders such as sickle cell disease (SCD), which could improve treatment safety and lower costs if eventually adopted in the clinic. Instead of a standard method that requires a round of chemotherapy before externally-edited cells…
The European Commission has decided to revoke its conditional approval of Adakveo (crizanlizumab) for sickle cell disease (SCD) — meaning its developer, Novartis, will have to remove the antibody-based therapy from the market in all 27 countries that are part of the European Union. The decision came after…
A gene editing technology called adenosine base editing (ABE), wherein a single DNA building block is changed to increase fetal hemoglobin, may be more useful for treating sickle cell disease (SCD) than other gene editing techniques, a study suggests. “We showed that not all genetic approaches are equal. Base…
Pfizer has decided to end a treatment discovery program with Syros Pharmaceuticals that it inherited after acquiring Global Blood Therapeutics (GBT) last year, leaving Syros to seek another partner for the program, which targets two blood disorders, including sickle cell disease (SCD). The agreement termination was announced…
Genetic medicines company Scribe Therapeutics has expanded its collaboration with Sanofi to advance the development of a new wave of in vivo treatments for sickle cell disease (SCD) and other disorders. The collaboration leverages Scribe’s proprietary CRISPR X-Editing technologies and Sanofi’s targeted non-viral delivery technologies for the…
Researchers at Rice University in Texas have been awarded $2.6 million to further investigate questions surrounding the safety and efficacy of gene editing as a potentially curative treatment for sickle cell disease (SCD). The four-year grant from the National Institutes of Health (NIH) was awarded to Gang Bao, PhD,…
Sickle Cell 101 is teaming up this summer with Cleveland Browns player Donovan Peoples-Jones — known to fans as DPJ — and his Limitless Foundation Football Camp to raise awareness about sickle cell trait and hydration, both key issues for people living with disorders like sickle cell disease…
The Oman Ministry of Health has approved Endari (oral L-glutamine) for children, ages 5 and older, and adults with sickle cell disease (SCD), its developer Emmaus Life Sciences has announced. The disease affects around 3,000 people in Oman, with about 6% of the population estimated to carry…
The fourth annual Cheek Week, an effort to include more blood stem cell donors in the Be The Match Registry will be featured as part of July’s African American Bone Marrow Awareness Month. The registry seeks to identify people who might be candidates to donate blood stem cells, which…
Recent Posts
- Researchers aim to repurpose diabetes drug to treat SCD kidneys
- Alzheimer’s drug memantine may help prevent SCD crises, especially in kids
- Red blood cell breakdown may drive cognitive problems in SCD
- Looking back at the 5 worst sickle cell crises of my life
- Fetal hemoglobin protects against sickle cell lung problems: Study
- Reflecting on a year of choosing myself while living with sickle cell disease
- New year, old goals, because repeating health resolutions works for sickle cell
- Researchers compare gene therapies for sickle cell disease in mice
- Emmaus to sell North American rights to sickle cell treatment Endari
- For sickle cell patients, developing self-advocacy skills starts in childhood